Global Nicotine Replacement Therapy for Smoking Cessation Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical
Publisher : MRA | Format : PDF
Global Nicotine Replacement Therapy for Smoking Cessation Market Research Report 2024
NRT, or Nicotine Replacement Therapy, refers to a range of smoking cessation aids that are designed to help individuals quit smoking by providing them with controlled doses of nicotine. NRT products are available in various forms, such as nicotine gum, patches, lozenges, nasal sprays, and inhalers. These aids work by delivering nicotine to the body without the harmful toxins and chemicals found in tobacco smoke, thereby reducing withdrawal symptoms and cravings associated with quitting smoking.
According to MRAResearch’s new survey, global Nicotine Replacement Therapy for Smoking Cessation market is projected to reach US$ 727.3 million in 2033, increasing from US$ 524 million in 2022, with the CAGR of 4.8% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Nicotine Replacement Therapy for Smoking Cessation market research.
Key companies engaged in the Nicotine Replacement Therapy for Smoking Cessation industry include Pfizer, Cipla, Novartis, GlaxoSmithKline, Johnson & Johnson, Philip Morris, Perrigo Company, Alkalon and Ventus Medical, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Nicotine Replacement Therapy for Smoking Cessation were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Nicotine Replacement Therapy for Smoking Cessation market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Nicotine Replacement Therapy for Smoking Cessation market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Pfizer
Cipla
Novartis
GlaxoSmithKline
Johnson & Johnson
Philip Morris
Perrigo Company
Alkalon
Ventus Medical
Segment by Type
Sprays and Inhalers
Gums
Patches
Lozenges
Pharmacy
Supermarket
Hospital
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Nicotine Replacement Therapy for Smoking Cessation report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source
According to MRAResearch’s new survey, global Nicotine Replacement Therapy for Smoking Cessation market is projected to reach US$ 727.3 million in 2033, increasing from US$ 524 million in 2022, with the CAGR of 4.8% during the period of 2023 to 2033. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Nicotine Replacement Therapy for Smoking Cessation market research.
Key companies engaged in the Nicotine Replacement Therapy for Smoking Cessation industry include Pfizer, Cipla, Novartis, GlaxoSmithKline, Johnson & Johnson, Philip Morris, Perrigo Company, Alkalon and Ventus Medical, etc. Among those companies, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % value of Nicotine Replacement Therapy for Smoking Cessation were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Nicotine Replacement Therapy for Smoking Cessation market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2023-2033), aims to help readers to get a comprehensive understanding of global Nicotine Replacement Therapy for Smoking Cessation market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Pfizer
Cipla
Novartis
GlaxoSmithKline
Johnson & Johnson
Philip Morris
Perrigo Company
Alkalon
Ventus Medical
Segment by Type
Sprays and Inhalers
Gums
Patches
Lozenges
Segment by Application
Pharmacy
Supermarket
Hospital
Other
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
The Nicotine Replacement Therapy for Smoking Cessation report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Global market size, regional market size. Market Opportunities and Challenges
Chapter 3Companies’ Competition Patterns
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6 to 10Country Level Value Analysis
Chapter 11Companies' Outline
Chapter 12Market Conclusions
Chapter 13Research Methodology and Data Source